{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:27:55Z","timestamp":1792718875178,"version":"4.5.0"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Guillain-Barr\u00e9 syndrome (GBS) is a rare, frequently postinfectious neuromuscular emergency and the leading cause of acute paralytic neuropathy worldwide. GBS incidence varies considerably across geographic regions, owing predominantly to different infectious exposures. In GBS, antecedent infection leads to production of immunoglobulin G and immunoglobulin M antibodies that cross-react with the myelin sheath and axons of peripheral nerves. These antibodies activate the classical complement pathway, which plays a key role in peripheral nerve injury regardless of autoantibody binding to myelin or axons as a target. The heterogeneous clinical presentation and progression of GBS symptoms have long been attributed to binary axonal and demyelinating neurophysiologic classifications; however, evolving evidence indicates that these pathophysiologic processes overlap. Intravenous immunoglobulin and plasma exchange, the current standard-of-care therapies in GBS, both reduce autoantibody levels and complement activation, thereby aiming to address this convergence of pathophysiology. However, these therapies only partially decrease antibody levels and complement activity and require extended courses of treatment (5\u202fdays for intravenous immunoglobulin and 7\u201314\u202fdays for plasma exchange), limiting their effectiveness in addressing acute neuronal damage during the active phase of disease. Given its evolutionary role in antibody binding and activating the classical complement pathway, the complement component C1q has been proposed as a therapeutic target in GBS. The clinical trial program of the C1q inhibitor ANX005, including placebo-controlled, double-blind phase 1b and phase 3 trials in GBS, provides insight into the pathophysiology of GBS and the efficacy of C1q inhibition regardless of neurophysiologic classification or geographic location.<\/jats:p>","DOI":"10.3389\/fneur.2025.1572949","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T09:36:48Z","timestamp":1747215408000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Evolving understanding of Guillain-Barr\u00e9 syndrome pathophysiology and the central role of the classical complement pathway in axonal injury"],"prefix":"10.3389","volume":"16","author":[{"given":"Kenneth C.","family":"Gorson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12974-021-02319-4","article-title":"Global, regional, and national burden of Guillain-Barr\u00e9 syndrome and its underlying causes from 1990 to 2019","volume":"18","author":"Bragazzi","year":"2021","journal-title":"J Neuroinflammation"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"100098","DOI":"10.1016\/j.gloepi.2023.100098","article-title":"Incidence of Guillain-Barr\u00e9 syndrome in the world between 1985 and 2020: a systematic review","volume":"5","author":"Wachira","year":"2023","journal-title":"Glob Epidemiol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.52768\/2766-7820\/2618","article-title":"Guillain-Barre syndrome ensuing dengue fever in a filipino male: a case report","volume":"4","author":"Co","year":"2023","journal-title":"J Clin Images Med Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41582-021-00467-y","article-title":"Guillain-Barr\u00e9 syndrome in low-income and middle-income countries: challenges and prospects","volume":"17","author":"Papri","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"608130","DOI":"10.3389\/fphar.2021.608130","article-title":"Intensive care and treatment of severe Guillain-Barr\u00e9 syndrome","volume":"12","author":"Shang","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41572-024-00580-4","article-title":"Guillain\u2013Barr\u00e9 syndrome","volume":"10","author":"Leonhard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/brain\/awy232","article-title":"Regional variation of Guillain-Barr\u00e9 syndrome","volume":"141","author":"Doets","year":"2018","journal-title":"Brain"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1600-0404.2011.01503.x","article-title":"Clinical characteristics of Guillain-Barr\u00e9 syndrome in a tropical country: a Brazilian experience","volume":"125","author":"Dourado","year":"2012","journal-title":"Acta Neurol Scand"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1212\/WNL.0b013e3182904fcc","article-title":"Mortality in Guillain-Barre syndrome","volume":"80","author":"van den Berg","year":"2013","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.17219\/acem\/186949","article-title":"Prognostic factors associated with worse outcomes in patients with GBS: a systematic review","volume":"34","author":"Grelowska","year":"2024","journal-title":"Adv Clin Exp Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.4103\/0972-2327.91942","article-title":"Mortality in mechanically ventilated patients of Guillain Barr\u00e9 syndrome","volume":"14","author":"Netto","year":"2011","journal-title":"Ann Indian Acad Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/ene.15204","article-title":"Increased mortality following Guillain-Barr\u00e9 syndrome: a population-based cohort study","volume":"29","author":"Levison","year":"2022","journal-title":"Eur J Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"79991","DOI":"10.18632\/oncotarget.20620","article-title":"Long-term prognosis of Guillain-Barr\u00e9 syndrome not determined by treatment options?","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s004150170157","article-title":"Long-term sensory deficit after Guillain-Barr\u00e9 syndrome","volume":"248","author":"Bernsen","year":"2001","journal-title":"J Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/dmcn.15693","article-title":"Long-term outcomes of paediatric Guillain-Barr\u00e9 syndrome","volume":"66","author":"Estublier","year":"2024","journal-title":"Dev Med Child Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1017\/cjn.2018.12","article-title":"Three-year follow-up study in patients with Guillain-Barr\u00e9 syndrome","volume":"45","author":"Martic","year":"2018","journal-title":"Can J Neurol Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1212\/WNL.0b013e3181f88345","article-title":"Pain in Guillain-Barre syndrome: a long-term follow-up study","volume":"75","author":"Ruts","year":"2010","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.4314\/mmj.v35i3.4","article-title":"Three-year follow-up outcomes of adult patients with Guillain-Barr\u00e9 syndrome after rehabilitation","volume":"35","author":"Uz","year":"2023","journal-title":"Malawi Med J"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1484661","DOI":"10.3389\/fneur.2024.1484661","article-title":"Mortality and its predictors among patients with Guillain-Barr\u00e9 syndrome in the intensive care unit of a low-income country, Ethiopia: a multicenter retrospective cohort study","volume":"15","author":"Bayu","year":"2024","journal-title":"Front Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/jns.12215","article-title":"High mortality from Guillain-Barr\u00e9 syndrome in Bangladesh","volume":"22","author":"Ishaque","year":"2017","journal-title":"J Peripher Nerv Syst"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.it.2022.02.003","article-title":"Guillain-Barr\u00e9 syndrome: expanding the concept of molecular mimicry","volume":"43","author":"Laman","year":"2022","journal-title":"Trends Immunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/jns.12469","article-title":"Antecedent infections in Guillain-Barr\u00e9 syndrome in endemic areas of arbovirus transmission: a multinational case-control study","volume":"26","author":"Leonhard","year":"2021","journal-title":"J Peripher Nerv Syst"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e1299","DOI":"10.1212\/WNL.0000000000200885","article-title":"An international perspective on preceding infections in Guillain-Barr\u00e9 syndrome: the IGOS-1000 cohort","volume":"99","author":"Leonhard","year":"2022","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1021\/acsinfecdis.2c00397","article-title":"Campylobacter jejuni and postinfectious autoimmune diseases: a proof of concept in glycobiology","volume":"8","author":"Stein","year":"2022","journal-title":"ACS Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"van den Berg","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"613628","DOI":"10.3389\/fnagi.2020.613628","article-title":"The neuroimmunology of Guillain-Barr\u00e9 syndrome and the potential role of an aging immune system","volume":"12","author":"Hagen","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1212\/NXI.0000000000000284","article-title":"Microarray screening of Guillain-Barr\u00e9 syndrome sera for antibodies to glycolipid complexes","volume":"3","author":"Halstead","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e82337","DOI":"10.1371\/journal.pone.0082337","article-title":"Antibodies to heteromeric glycolipid complexes in Guillain-Barr\u00e9 syndrome","volume":"8","author":"Rinaldi","year":"2013","journal-title":"PLoS One"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaf102","article-title":"Large-scale profiling of antibody reactivity to glycolipids in patients with Guillain-Barr\u00e9 syndrome","author":"Thomma","year":"2025","journal-title":"Brain"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1177\/1091581817740873","article-title":"Nonclinical development of ANX005: a humanized anti-C1q antibody for treatment of autoimmune and neurodegenerative diseases","volume":"36","author":"Lansita","year":"2017","journal-title":"Int J Toxicol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40478-016-0291-x","article-title":"C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy","volume":"4","author":"McGonigal","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"ref34","volume-title":"The complement system and innate immunity. Immunobiology: The immune system in health and disease","author":"Janeway","year":"2001"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/ana.410400414","article-title":"Acute motor axonal neuropathy: an antibody-mediated attack on axolemma","volume":"40","author":"Hafer-Macko","year":"1996","journal-title":"Ann Neurol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1002\/ana.410270707","article-title":"Assessment of current diagnostic criteria for Guillain-Barr\u00e9 syndrome","volume":"27","author":"Asbury","year":"1990","journal-title":"Ann Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1136\/jnnp.2004.051136","article-title":"Recovery patterns and long term prognosis for axonal Guillain-Barr\u00e9 syndrome","volume":"76","author":"Hiraga","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.5152\/npa.2017.16996","article-title":"Turkish childhood Guillan-Barre syndrome study group. Electrophysiological subtypes and prognostic factors of childhood Guillain-Barr\u00e9 syndrome","volume":"55","author":"Konu\u015fkan","year":"2018","journal-title":"Noro Psikiyatr Ars"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/mus.20520","article-title":"Electrophysiological subtypes and prognosis of childhood Guillain\u2013Barr\u00e9 syndrome in Japan","volume":"33","author":"Nagasawa","year":"2006","journal-title":"Muscle Nerve"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3389\/fneur.2019.00714","article-title":"Electrophysiological subtypes and prognostic factors of Guillain-Barre syndrome in northern China","volume":"10","author":"Tian","year":"2019","journal-title":"Front Neurol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1111\/ene.16073","article-title":"European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of Guillain-Barr\u00e9 syndrome","volume":"30","author":"van Doorn","year":"2023","journal-title":"Eur J Neurol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/mus.23477","article-title":"Electrophysiological subtypes and prognosis of Guillain-Barr\u00e9 syndrome in northeastern China","volume":"47","author":"Ye","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s41983-023-00646-2","article-title":"The early clinical and laboratory predictors of GBS outcome: hospital-based study, Assiut University, upper Egypt","volume":"59","author":"Khedr","year":"2023","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"105072","DOI":"10.1016\/j.ebiom.2024.105072","article-title":"Dynamics and prognostic value of serum neurofilament light chain in Guillain-Barr\u00e9 syndrome","volume":"102","author":"van Tilburg","year":"2024","journal-title":"EBioMedicine"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/ane.12927","article-title":"Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barr\u00e9 syndrome: a pilot study","volume":"138","author":"Axelsson","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/mus.23752","article-title":"Serial cerebrospinal fluid neurofilament heavy chain levels in severe Guillain-Barr\u00e9 syndrome","volume":"48","author":"Dujmovic","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/jnnp-2020-323899","article-title":"Serum neurofilament light chain predicts long-term prognosis in Guillain-Barr\u00e9 syndrome patients","volume":"92","author":"Mart\u00edn-Aguilar","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s13760-020-01413-3","article-title":"Inflammatory oedema of nerve trunks may be pathogenic in very early Guillain-Barr\u00e9 syndrome","volume":"120","author":"Berciano","year":"2020","journal-title":"Acta Neurol Belg"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cnp.2019.11.003","article-title":"Very early Guillain-Barr\u00e9 syndrome: a clinical-electrophysiological and ultrasonographic study","volume":"5","author":"Berciano","year":"2019","journal-title":"Clin Neurophysiol Pract"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/j.clinph.2004.05.009","article-title":"Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy","volume":"115","author":"Vucic","year":"2004","journal-title":"Clin Neurophysiol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e16335","DOI":"10.1111\/ene.16335","article-title":"Electrodiagnostic subtyping in Guillain-Barr\u00e9 syndrome patients in the international Guillain-Barr\u00e9 outcome study","volume":"31","author":"Arends","year":"2024","journal-title":"Eur J Neurol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2215153","DOI":"10.1080\/21645515.2023.2215153","article-title":"Progress in Guillain-Barr\u00e9 syndrome immunotherapy\u2014a narrative review of new strategies in recent years","volume":"19","author":"Yao","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrneurol.2016.172","article-title":"Guillain-Barr\u00e9 syndrome: a century of progress","volume":"12","author":"Goodfellow","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"100468","DOI":"10.1016\/j.ensci.2023.100468","article-title":"Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barr\u00e9 syndrome (GBS) in patients with severe symptoms: a systematic review and meta-analysis","volume":"31","author":"Zaki","year":"2023","journal-title":"eNeurologicalSci"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1212\/wnl.59.12_suppl_6.s13","article-title":"Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies","volume":"59","author":"Dalakas","year":"2002","journal-title":"Neurology"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"CD002063","DOI":"10.1002\/14651858.CD002063.pub6","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","volume":"2019","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2018.1493415","article-title":"Immunotherapy of Guillain-Barr\u00e9 syndrome","volume":"14","author":"Liu","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/antib12010020","article-title":"Intravenous immunoglobulins as immunomodulators in autoimmune diseases and reproductive medicine","volume":"12","author":"Velikova","year":"2023","journal-title":"Antibodies (Basel)"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"19170","DOI":"10.1038\/s41598-021-98501-y","article-title":"Real-world treatment of adult patients with Guillain-Barr\u00e9 syndrome over the last two decades","volume":"11","author":"Rath","year":"2021","journal-title":"Sci Rep"},{"key":"ref61","year":""},{"key":"ref62","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1212\/WNL.35.8.1096","article-title":"Plasmapheresis and acute Guillain-Barr\u00e9 syndrome","volume":"35","year":"1985","journal-title":"Neurology"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barr\u00e9 syndrome","volume":"326","author":"van der Mech\u00e9","year":"1992","journal-title":"N Engl J Med"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.blre.2017.02.003","article-title":"Complementopathies","volume":"31","author":"Baines","year":"2017","journal-title":"Blood Rev"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1182\/blood.v98.10.3136","article-title":"Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect","volume":"98","author":"Bleeker","year":"2001","journal-title":"Blood"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1055\/s-0037-1613331","article-title":"Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor","volume":"88","author":"Hansen","year":"2002","journal-title":"Thromb Haemost"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1001\/archneur.63.7.930","article-title":"Plasma exchange in neuroimmunological disorders: part 1: rationale and treatment of inflammatory central nervous system disorders","volume":"63","author":"Lehmann","year":"2006","journal-title":"Arch Neurol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jneuroim.2010.08.023","article-title":"IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN","volume":"229","author":"Piepers","year":"2010","journal-title":"J Neuroimmunol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/jnnp-2016-314862","article-title":"Treatment dilemmas in Guillain-Barr\u00e9 syndrome","volume":"88","author":"Verboon","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jns.2007.08.005","article-title":"The morbidity and outcome of patients with Guillain-Barr\u00e9 syndrome admitted to the intensive care unit","volume":"264","author":"Dhar","year":"2008","journal-title":"J Neurol Sci"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s00415-005-0958-x","article-title":"Long term disability and social status change after Guillain-Barr\u00e9 syndrome","volume":"253","author":"Bersano","year":"2006","journal-title":"J Neurol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/jns5.12051","article-title":"Health-related quality of life in Guillain-Barr\u00e9 syndrome patients: a systematic review","volume":"19","author":"Darweesh","year":"2014","journal-title":"J Peripher Nerv Syst"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1212\/01.WNL.0000149521.65474.83","article-title":"Residual neuropathy in long-term population-based follow-up of Guillain-Barr\u00e9 syndrome","volume":"64","author":"Dornonville de la Cour","year":"2005","journal-title":"Neurology"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3109\/09638281003734474","article-title":"Guillain-Barre syndrome\u2013rehabilitation outcome, residual deficits and requirement of lower limb orthosis for locomotion at 1 year follow-up","volume":"32","author":"Gupta","year":"2010","journal-title":"Disabil Rehabil"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1007\/s00415-010-5653-x","article-title":"Factors associated with long-term functional outcomes and psychological sequelae in Guillain-Barre syndrome","volume":"257","author":"Khan","year":"2010","journal-title":"J Neurol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s00415-012-6806-x","article-title":"Long-term outcome in patients with Guillain-Barr\u00e9 syndrome requiring mechanical ventilation","volume":"260","author":"Witsch","year":"2013","journal-title":"J Neurol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.4103\/0972-2327.83087","article-title":"Treatment guidelines for Guillain-Barr\u00e9 syndrome","volume":"14","author":"Meena","year":"2011","journal-title":"Ann Indian Acad Neurol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/mus.28271","article-title":"Timing of intravenous immunoglobulin treatment and outcome in Guillain-Barr\u00e9 syndrome: is time nerve?","volume":"70","author":"Min","year":"2024","journal-title":"Muscle Nerve"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1212\/WNL.0000000000007719","article-title":"Current treatment practice of Guillain-Barr\u00e9 syndrome","volume":"93","author":"Verboon","year":"2019","journal-title":"Neurology"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/CND.0b013e3181f3dbbf","article-title":"Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barr\u00e9 syndrome: critical reassessment of effectiveness and cost-efficiency","volume":"12","author":"Oczko-Walker","year":"2010","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/ana.410410304","article-title":"The French cooperative group on plasma exchange in Guillain-Barr\u00e9 syndrome. Appropriate number of plasma exchanges in Guillain-Barr\u00e9 syndrome","volume":"41","year":"1997","journal-title":"Ann Neurol"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/jnnp-2019-321496","article-title":"Original research: second IVIg course in Guillain-Barr\u00e9 syndrome with poor prognosis: the non-randomised ISID study","volume":"91","author":"Verboon","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1474-4422(20)30494-4","article-title":"Second intravenous immunoglobulin dose in patients with Guillain-Barr\u00e9 syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial","volume":"20","author":"Walgaard","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/ana.410390512","article-title":"Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy","volume":"39","author":"Hafer-Macko","year":"1996","journal-title":"Ann Neurol"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1016\/j.molimm.2009.04.027","article-title":"The role of the anaphylatoxins in health and disease","volume":"46","author":"Klos","year":"2009","journal-title":"Mol Immunol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"958392","DOI":"10.3389\/fimmu.2022.958392","article-title":"Anaphylatoxins spark the flame in early autoimmunity","volume":"13","author":"Schanzenbacher","year":"2022","journal-title":"Front Immunol"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/brain\/awt285","article-title":"Diagnosis of Guillain-Barr\u00e9 syndrome and validation of Brighton criteria","volume":"137","author":"Fokke","year":"2014","journal-title":"Brain"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41577-019-0168-x","article-title":"New insights into the immune functions of complement","volume":"19","author":"Reis","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.imbio.2006.11.009","article-title":"The phylogeny of the complement system and the origins of the classical pathway","volume":"212","author":"Dodds","year":"2007","journal-title":"Immunobiology"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/s0161-5890(03)00109-3","article-title":"\"Eat me\" and \"don't eat me\" signals govern the innate immune response and tissue repair in the CNS: emphasis on the critical role of the complement system","volume":"40","author":"Elward","year":"2003","journal-title":"Mol Immunol"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"e140966","DOI":"10.1172\/JCI140966","article-title":"Endothelial C3a receptor mediates vascular inflammation and blood-brain barrier permeability during aging","volume":"131","author":"Propson","year":"2021","journal-title":"J Clin Invest"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s13311-022-01253-4","article-title":"Immunoglobulin and monoclonal antibody therapies in Guillain-Barr\u00e9 syndrome","volume":"19","author":"Rajabally","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3389\/fncel.2014.00380","article-title":"Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis","volume":"8","author":"Orsini","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"ref95","author":"Suri","year":"2021"},{"key":"ref96","author":"Kroon","year":"2024"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1136\/jnnp-2020-324445","article-title":"CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS","volume":"92","author":"Capodivento","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref98","author":"Kroon","year":"2024"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1572949\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T09:36:49Z","timestamp":1747215409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1572949\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":98,"alternative-id":["10.3389\/fneur.2025.1572949"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1572949","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"article-number":"1572949"}}